Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

BACKGROUND: Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by these drugs and their severity especially in patients with history of inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Escandon, Julia, Peacock, Stephanie, Trabolsi, Asaad, Thomas, David B., Layka, Ayman, Lutzky, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240303/
https://www.ncbi.nlm.nih.gov/pubmed/28105370
http://dx.doi.org/10.1186/s40425-016-0205-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240303/
https://www.ncbi.nlm.nih.gov/pubmed/28105370
http://dx.doi.org/10.1186/s40425-016-0205-2

Ejemplares similares